Lantheus Holdings, Inc. (LNTH): Results of Operations and Financial Condition
Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lantheus Reports Second Quarter 2026 Financial Results • Worldwide revenue of $388.2 million in the second quarter of 2026 • GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 • Ad
How this was made
The 30-second read
Why it matters
Traders should focus on deal-spread dynamics, CVR valuation, and the timeline to proxy filing and special meeting, since full-year guidance is suspended.
Market read
Material M&A terms plus guidance suspension make this a primary event for LNTH positioning and hedging decisions.
What to watch
Guidance is suspended and no conference call is planned, which can reduce near-term transparency and raise uncertainty around operating trajectory into the proxy/closing timeline.
Background
Lantheus filed an 8-K with Q2 2026 operating results and a definitive merger agreement announced August 3, 2026.
Ticker impact
Lantheus reported Q2 results and disclosed a definitive all-cash merger agreement with Curium at $102.50 per share plus CVRs.
Likely positive bias on deal certainty, with volatility around regulatory/closing risk and CVR milestone expectations.
The filing includes specific per-share consideration, total transaction value, board approval, and guidance suspension, which are direct inputs to deal-spread and event-driven positioning.
Market effects
Radiopharmaceutical M&A signal may re-rate deal expectations and valuation frameworks across diagnostics and therapeutics peers.
Limited direct regional effect; primarily US-listed event-driven flow into LNTH and radiopharma complex.
Transaction targets a platform spanning more than 70 countries, potentially affecting global competitive positioning in radiopharma supply chains.
Counterpoint
The CVRs tied to commercial milestones through 2030 can be a valuation overhang if milestones are harder than implied, increasing downside in deal-spread trades.
Key entities
- public_companyLantheus Holdings, Inc.
Radiopharmaceutical-focused company reporting Q2 2026 results and entering a definitive merger agreement with Curium.
- acquirerCurium US Holdings LLC
Acquiring entity that will purchase all outstanding Lantheus shares for cash plus CVRs.
